ContraFect Corp (NASDAQ:CFRX)’s stock price traded up 5.4% during trading on Thursday . The company traded as high as $0.40 and last traded at $0.39, 155,000 shares traded hands during trading. A decline of 81% from the average session volume of 821,775 shares. The stock had previously closed at $0.37.
A number of equities research analysts have recently commented on the company. ValuEngine upgraded ContraFect from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Maxim Group restated a “buy” rating and set a $2.00 target price on shares of ContraFect in a research report on Friday.
The stock has a market capitalization of $30.10 million, a price-to-earnings ratio of -1.02 and a beta of 0.15. The stock has a 50-day moving average price of $0.38 and a 200 day moving average price of $0.45. The company has a current ratio of 4.15, a quick ratio of 4.15 and a debt-to-equity ratio of 0.37.
A number of institutional investors have recently modified their holdings of CFRX. Oracle Investment Management Inc. lifted its stake in ContraFect by 13.1% in the 2nd quarter. Oracle Investment Management Inc. now owns 6,356,649 shares of the biotechnology company’s stock valued at $3,242,000 after buying an additional 735,450 shares in the last quarter. SG Americas Securities LLC purchased a new position in ContraFect in the 2nd quarter worth approximately $343,000. White Pine Capital LLC lifted its stake in ContraFect by 207.9% in the 1st quarter. White Pine Capital LLC now owns 907,430 shares of the biotechnology company’s stock worth $361,000 after purchasing an additional 612,700 shares in the last quarter. Trellus Management Company LLC purchased a new position in ContraFect in the 2nd quarter worth approximately $295,000. Finally, Hartwell J M Limited Partnership lifted its stake in ContraFect by 40.0% in the 2nd quarter. Hartwell J M Limited Partnership now owns 140,000 shares of the biotechnology company’s stock worth $71,000 after purchasing an additional 40,000 shares in the last quarter. 34.86% of the stock is currently owned by hedge funds and other institutional investors.
About ContraFect (NASDAQ:CFRX)
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Recommended Story: Trading Strategy
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.